Search

Your search keyword '"Mhawech-Fauceglia, Paulette"' showing total 569 results
Start Over Author "Mhawech-Fauceglia, Paulette"
569 results on '"Mhawech-Fauceglia, Paulette"'

1. Author Correction: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

Author

Bateman, Nicholas W., Abulez, Tamara, Soltis, Anthony R., McPherson, Andrew, Choi, Seongmin, Garsed, Dale W., Pandey, Ahwan, Tian, Chunqiao, Hood, Brian L., Conrads, Kelly A., Teng, Pang-ning, Oliver, Julie, Gist, Glenn, Mitchell, Dave, Litzi, Tracy J., Tarney, Christopher M., Crothers, Barbara A., Mhawech-Fauceglia, Paulette, Dalgard, Clifton L., Wilkerson, Matthew D., Pierobon, Mariaelena, Petricoin, Emanuel F., Yan, Chunhua, Meerzaman, Daoud, Bodelon, Clara, Wentzensen, Nicolas, Lee, Jerry S. H., Huntsman, David G., Shah, Sohrab, Shriver, Craig D., Phippen, Neil T., Darcy, Kathleen M., Bowtell, David D. L., Conrads, Thomas P., and Maxwell, G. Larry

Published
2024
Full Text
View/download PDF

2. Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

Author

Bateman, Nicholas W., Abulez, Tamara, Soltis, Anthony R., McPherson, Andrew, Choi, Seongmin, Garsed, Dale W., Pandey, Ahwan, Tian, Chunqiao, Hood, Brian L., Conrads, Kelly A., Teng, Pang-ning, Oliver, Julie, Gist, Glenn, Mitchell, Dave, Litzi, Tracy J., Tarney, Christopher M., Crothers, Barbara A., Mhawech-Fauceglia, Paulette, Dalgard, Clifton L., Wilkerson, Matthew D., Pierobon, Mariaelena, Petricoin, Emanuel F., Yan, Chunhua, Meerzaman, Daoud, Bodelon, Clara, Wentzensen, Nicolas, Lee, Jerry S. H., Huntsman, David G., Shah, Sohrab, Shriver, Craig D., Phippen, Neil T., Darcy, Kathleen M., Bowtell, David D. L., Conrads, Thomas P., and Maxwell, G. Larry

Published
2024
Full Text
View/download PDF

3. The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study

Author

Mhawech-Fauceglia, Paulette, McCarthy, Denis, Tonooka, Akiko, Scambia, Giovanni, Garcia, Yolanda, Dundr, Pavel, Mills, Anne M., Moore, Kathleen, Sanada, Sakiko, Bradford, Leslie, Stella, Giulia Carlo, Bookman, Michael, Sharma, Sudarshan K., Selle, Frederic, Molinero, Luciana, He, Yvette, Khor, Victor, Landen, Charles, and Lin, Yvonne G.

Published
2024
Full Text
View/download PDF

8. Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer.

Author

Corona, Rosario I, Seo, Ji-Heui, Lin, Xianzhi, Hazelett, Dennis J, Reddy, Jessica, Fonseca, Marcos AS, Abassi, Forough, Lin, Yvonne G, Mhawech-Fauceglia, Paulette Y, Shah, Sohrab P, Huntsman, David G, Gusev, Alexander, Karlan, Beth Y, Berman, Benjamin P, Freedman, Matthew L, Gayther, Simon A, and Lawrenson, Kate

Subjects
Ovary, Humans, Ovarian Neoplasms, Muscle Proteins, DNA-Binding Proteins, Transcription Factors, Repressor Proteins, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, Binding Sites, Mutation, Polymorphism, Single Nucleotide, Adult, Aged, Middle Aged, Female, Kruppel-Like Transcription Factors, Gene Regulatory Networks, Enhancer Elements, Genetic, Gene Knockout Techniques, Epigenomics, PAX8 Transcription Factor, Whole Genome Sequencing, Carcinoma, Ovarian Epithelial, Chromatin Immunoprecipitation Sequencing, RNA-Seq
Abstract

The functional consequences of somatic non-coding mutations in ovarian cancer (OC) are unknown. To identify regulatory elements (RE) and genes perturbed by acquired non-coding variants, here we establish epigenomic and transcriptomic landscapes of primary OCs using H3K27ac ChIP-seq and RNA-seq, and then integrate these with whole genome sequencing data from 232 OCs. We identify 25 frequently mutated regulatory elements, including an enhancer at 6p22.1 which associates with differential expression of ZSCAN16 (P = 6.6 × 10-4) and ZSCAN12 (P = 0.02). CRISPR/Cas9 knockout of this enhancer induces downregulation of both genes. Globally, there is an enrichment of single nucleotide variants in active binding sites for TEAD4 (P = 6 × 10-11) and its binding partner PAX8 (P = 2×10-10), a known lineage-specific transcription factor in OC. In addition, the collection of cis REs associated with PAX8 comprise the most frequently mutated set of enhancers in OC (P = 0.003). These data indicate that non-coding somatic mutations disrupt the PAX8 transcriptional network during OC development.

Published
2020

9. A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development

Author

Lawrenson, Kate, Fonseca, Marcos AS, Liu, Annie Y, Dezem, Felipe Segato, Lee, Janet M, Lin, Xianzhi, Corona, Rosario I, Abbasi, Forough, Vavra, Kevin C, Dinh, Huy Q, Gill, Navjot Kaur, Seo, Ji-Heui, Coetzee, Simon, Lin, Yvonne G, Pejovic, Tanja, Mhawech-Fauceglia, Paulette, Rowat, Amy C, Drapkin, Ronny, Karlan, Beth Y, Hazelett, Dennis J, Freedman, Matthew L, Gayther, Simon A, and Noushmehr, Houtan

Subjects
Biological Sciences, Rare Diseases, Ovarian Cancer, Cancer, Prevention, 2.1 Biological and endogenous factors, Aetiology, Adult, Aged, Cell Line, Cell Line, Tumor, Epithelial Cells, Epithelial-Mesenchymal Transition, Fallopian Tubes, Female, Gene Expression Regulation, Neoplastic, Humans, Machine Learning, Middle Aged, Ovarian Neoplasms, Ovary, RNA-Seq, SOXF Transcription Factors, Single-Cell Analysis, Transcriptome, RNA-seq, SOX18, dual origins, fallopian tube secretory epithelial cell, high-grade serous ovarian cancer, machine learning, one-class logistic regression models, ovarian surface epithelial cell, single-cell RNA-seq, super enhancers, transcription factors, Biochemistry and Cell Biology, Medical Physiology, Biological sciences
Abstract

Fallopian tube secretory epithelial cells (FTSECs) are likely the main precursor cell type of high-grade serous ovarian cancers (HGSOCs), but these tumors may also arise from ovarian surface epithelial cells (OSECs). We profiled global landscapes of gene expression and active chromatin to characterize molecular similarities between OSECs (n = 114), FTSECs (n = 74), and HGSOCs (n = 394). A one-class machine learning algorithm predicts that most HGSOCs derive from FTSECs, with particularly high FTSEC scores in mesenchymal-type HGSOCs (padj < 8 × 10-4). However, a subset of HGSOCs likely derive from OSECs, particularly HGSOCs of the proliferative type (padj < 2 × 10-4), suggesting a dualistic model for HGSOC origins. Super-enhancer (SE) landscapes were also more similar between FTSECs and HGSOCs than between OSECs and HGSOCs (p < 2.2 × 10-16). The SOX18 transcription factor (TF) coincided with a HGSOC-specific SE, and ectopic overexpression of SOX18 in FTSECs caused epithelial-to-mesenchymal transition, indicating that SOX18 plays a role in establishing the mesenchymal signature of fallopian-derived HGSOCs.

Published
2019

10. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Author

Boughey, Judy C, Alvarado, Michael D, Lancaster, Rachael B, Symmans, W Fraser, Mukhtar, Rita, Wong, Jasmine M, Ewing, Cheryl A, Potter, David A, Tuttle, Todd M, Hieken, Tina J, Carter, Jodi M, Jakub, James W, Kaplan, Henry G, Buchanan, Claire L, Jaskowiak, Nora T, Sattar, Husain A, Mueller, Jeffrey, Nanda, Rita, Isaacs, Claudine J, Pohlmann, Paula R, Lynce, Filipa, Tousimis, Eleni A, Zeck, Jay C, Lee, M Catherine, Lang, Julie E, Mhawech-Fauceglia, Paulette, Rao, Roshni, Taback, Bret, Goodellas, Constantine, Chen, Margaret, Kalinsky, Kevin M, Hibshoosh, Hanina, Killelea, Brigid, Sanft, Tara, Hirst, Gillian L, Asare, Smita, Matthews, Jeffrey B, Perlmutter, Jane, Esserman, Laura J, and I-SPY2 Investigators

Subjects
I-SPY2 Investigators
Abstract

[This corrects the article DOI: 10.1038/s41523-018-0074-6.].

Published
2019

12. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Author

Adamson, Kathi, Albain, Kathy S., Asare, Adam L., Asare, Smita M., Balassanian, Ron, Beckwith, Heather, Berry, Scott M., Berry, Donald A., Boughey, Judy C., Buxton, Meredith B., Chen, Yunn-Yi, Chen, Beiyun, Chien, A. Jo, Chui, Stephen Y., Clark, Amy S., Clennell, Julia L., Datnow, Brian, DeMichele, Angela M., Duan, Xiuzhen, Edmiston, Kirsten K., Elias, Anthony D., Ellis, Erin D., Esserman, Laura L., Euhus, David M., Fadare, Oluwole, Fan, Fang, Feldman, Michael D, Forero-Torres, Andres, Haley, Barbara B., Han, Hyo S., Harada, Shuko, Haugen, Patricia, Helsten, Teresa, Hirst, Gillian L., Hylton, Nola M., Isaacs, Claudine, Kemmer, Kathleen, Khan, Qamar J., Khazai, Laila, Klein, Molly E., Krings, Gregor, Lang, Julie E., LeBeau, Lauren G., Leyland-Jones, Brian, Liu, Minetta C., Lo, Shelly, Lu, Janice, Magliocco, Anthony, Matthews, Jeffrey B., Melisko, Michelle E., Mhawech-Fauceglia, Paulette, Moulder, Stacy L., Murthy, Rashmi K., Nanda, Rita, Northfelt, Donald W., Ocal, Idris T., Olopade, Olufunmilayo, Pambuccian, Stefan, Paoloni, Melissa, Park, John W., Parker, Barbara A., Perlmutter, Jane, Peterson, Garry, Pusztai, Lajos, Rendi, Mara, Rugo, Hope S., Sahoo, Sunati, Sams, Sharon, Sanil, Ashish, Sattar, Husain, Schwab, Richard B., Singhrao, Ruby, Steeg, Katherine, Stringer-Reasor, Erica, Symmans, W. Fraser, Tawfik, Ossama, Tripathy, Debasish, Troxell, Megan L., van't Veer, Laura J., Venters, Sara J., Vinh, Tuyethoa, Viscusi, Rebecca K., Wallace, Anne M., Wei, Shi, Wilson, Amy, Yau, Christina, Yee, Douglas, Zeck, Jay C., Osdoit, Marie, van der Noordaa, Marieke, Shad, Sonal, Wei, Jane, de Croze, Diane, Hamy, Anne-Sophie, Laé, Marick, Reyal, Fabien, Sonke, Gabe S, Steenbruggen, Tessa G, van Seijen, Maartje, Wesseling, Jelle, Martín, Miguel, del Monte-Millán, Maria, López-Tarruella, Sara, Boughey, Judy C, Goetz, Matthew P, Hoskin, Tanya, Gould, Rebekah, Valero, Vicente, Edge, Stephen B, Abraham, Jean E, Bartlett, John M S, Caldas, Carlos, Dunn, Janet, Earl, Helena, Hayward, Larry, Hiller, Louise, Provenzano, Elena, Sammut, Stephen-John, Thomas, Jeremy S, Cameron, David, Graham, Ashley, Hall, Peter, Mackintosh, Lorna, Godwin, Andrew K, Schwensen, Kelsey, Sharma, Priyanka, DeMichele, Angela M, Cole, Kimberly, Kim, Mi-Ok, van 't Veer, Laura J, Esserman, Laura J, and Symmans, W Fraser

Published
2022
Full Text
View/download PDF

13. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Author

Boughey, Judy C, Alvarado, Michael D, Lancaster, Rachael B, Fraser Symmans, W, Mukhtar, Rita, Wong, Jasmine M, Ewing, Cheryl A, Potter, David A, Tuttle, Todd M, Hieken, Tina J, Carter, Jodi M, Jakub, James W, Kaplan, Henry G, Buchanan, Claire L, Jaskowiak, Nora T, Sattar, Husain A, Mueller, Jeffrey, Nanda, Rita, Isaacs, Claudine J, Pohlmann, Paula R, Lynce, Filipa, Tousimis, Eleni A, Zeck, Jay C, Lee, M Catherine, Lang, Julie E, Mhawech-Fauceglia, Paulette, Rao, Roshni, Taback, Bret, Chen, Margaret, Kalinsky, Kevin M, Hibshoosh, Hanina, Killelea, Brigid, Sanft, Tara, Hirst, Gillian L, Asare, Smita, Matthews, Jeffrey B, Perlmutter, Jane, Esserman, Laura J, and and I-SPY 2 Investigators

Subjects
and I-SPY 2 Investigators, Clinical Trials and Supportive Activities, Clinical Research, Patient Safety, Cancer
Abstract

Advances in the surgical management of the axilla in patients treated with neoadjuvant chemotherapy, especially those with node positive disease at diagnosis, have led to changes in practice and more judicious use of axillary lymph node dissection that may minimize morbidity from surgery. However, there is still significant confusion about how to optimally manage the axilla, resulting in variation among practices. From the viewpoint of drug development, assessment of response to neoadjuvant chemotherapy remains paramount and appropriate assessment of residual disease-the primary endpoint of many drug therapy trials in the neoadjuvant setting-is critical. Therefore decreasing the variability, especially in a multicenter clinical trial setting, and establishing a minimum standard to ensure consistency in clinical trial data, without mandating axillary lymph node dissection, for all patients is necessary. The key elements which include proper staging and identification of nodal involvement at diagnosis, and appropriately targeted management of the axilla at the time of surgical resection are presented. The following protocols have been adopted as standard procedure by the I-SPY2 trial for management of axilla in patients with node positive disease, and present a framework for prospective clinical trials and practice.

Published
2018

18. Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element

Author

Matsuo, Koji, Takazawa, Yutaka, Ross, Malcolm S., Elishaev, Esther, Yunokawa, Mayu, Sheridan, Todd B., Bush, Stephen H., Klobocista, Merieme M., Blake, Erin A., Takano, Tadao, Baba, Tsukasa, Satoh, Shinya, Shida, Masako, Ikeda, Yuji, Adachi, Sosuke, Yokoyama, Takuhei, Takekuma, Munetaka, Yanai, Shiori, Takeuchi, Satoshi, Nishimura, Masato, Iwasaki, Keita, Johnson, Marian S., Yoshida, Masayuki, Hakam, Ardeshir, Machida, Hiroko, Mhawech-Fauceglia, Paulette, Ueda, Yutaka, Yoshino, Kiyoshi, Kajiwara, Hiroshi, Hasegawa, Kosei, Yasuda, Masanori, Miyake, Takahito M., Moriya, Takuya, Yuba, Yoshiaki, Morgan, Terry, Fukagawa, Tomoyuki, Pejovic, Tanja, Nagano, Tadayoshi, Sasaki, Takeshi, Richmond, Abby M., Post, Miriam D., Shahzad, Mian M.K., Im, Dwight D., Yoshida, Hiroshi, Omatsu, Kohei, Ueland, Frederick R., Kelley, Joseph L., Karabakhtsian, Rouzan G., and Roman, Lynda D.

Published
2018
Full Text
View/download PDF

21. Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma

Author

Matsuo, Koji, Takazawa, Yutaka, Ross, Malcolm S., Elishaev, Esther, Yunokawa, Mayu, Sheridan, Todd B., Bush, Stephen H., Klobocista, Merieme M., Blake, Erin A., Takano, Tadao, Baba, Tsukasa, Satoh, Shinya, Shida, Masako, Ikeda, Yuji, Adachi, Sosuke, Yokoyama, Takuhei, Takekuma, Munetaka, Yanai, Shiori, Takeuchi, Satoshi, Nishimura, Masato, Iwasaki, Keita, Johnson, Marian S., Yoshida, Masayuki, Hakam, Ardeshir, Machida, Hiroko, Mhawech-Fauceglia, Paulette, Ueda, Yutaka, Yoshino, Kiyoshi, Kajiwara, Hiroshi, Hasegawa, Kosei, Yasuda, Masanori, Miyake, Takahito M., Moriya, Takuya, Yuba, Yoshiaki, Morgan, Terry, Fukagawa, Tomoyuki, Pejovic, Tanja, Nagano, Tadayoshi, Sasaki, Takeshi, Richmond, Abby M., Post, Miriam D., Shahzad, Mian M. K., Im, Dwight D., Yoshida, Hiroshi, Enomoto, Takayuki, Omatsu, Kohei, Ueland, Frederick R., Kelley, Joseph L., Karabakhtsian, Rouzan G., and Roman, Lynda D.

Published
2018
Full Text
View/download PDF

23. Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer

Author

Garcia-Sayre, Jocelyn, primary, Lin, Yvonne G., additional, Matuso, Koji, additional, Tsao-Wei, Denice D., additional, Mhawech-Fauceglia, Paulette, additional, Louie, Stan, additional, Dong, Tiange, additional, Ciccone, Marcia A., additional, Brunette-Masi, Laurie L., additional, Pham, Huyen Q., additional, Yessaian, Annie A., additional, Groshen, Susan G., additional, Facio, Grace, additional, Aldana, Marissa, additional, Muderspach, Laila I., additional, Garcia, Agustin A., additional, and Roman, Lynda D., additional

Published
2023
Full Text
View/download PDF

28. Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint

Author

Boughey, Judy C., Alvarado, Michael D., Lancaster, Rachael B., Symmans, W. Fraser, Mukhtar, Rita, Wong, Jasmine M., Ewing, Cheryl A., Potter, David A., Tuttle, Todd M., Hieken, Tina J., Carter, Jodi M., Jakub, James W., Kaplan, Henry G., Buchanan, Claire L., Jaskowiak, Nora T., Sattar, Husain A., Mueller, Jeffrey, Nanda, Rita, Isaacs, Claudine J., Pohlmann, Paula R., Lynce, Filipa, Tousimis, Eleni A., Zeck, Jay C., Lee, M. Catherine, Lang, Julie E., Mhawech-Fauceglia, Paulette, Rao, Roshni, Taback, Bret, Goodellas, Constantine, Chen, Margaret, Kalinsky, Kevin M., Hibshoosh, Hanina, Killelea, Brigid, Sanft, Tara, Hirst, Gillian L., Asare, Smita, Matthews, Jeffrey B., Perlmutter, Jane, Esserman, Laura J., and I-SPY2 Investigators

Published
2019
Full Text
View/download PDF

32. Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma

Author

Matsuo, Koji, Takazawa, Yutaka, Ross, Malcolm S., Elishaev, Esther, Yunokawa, Mayu, Sheridan, Todd B., Bush, Stephen H., Klobocista, Merieme M., Blake, Erin A., Takano, Tadao, Baba, Tsukasa, Satoh, Shinya, Shida, Masako, Ikeda, Yuji, Adachi, Sosuke, Yokoyama, Takuhei, Takekuma, Munetaka, Yanai, Shiori, Takeuchi, Satoshi, Nishimura, Masato, Iwasaki, Keita, Johnson, Marian S., Yoshida, Masayuki, Hakam, Ardeshir, Machida, Hiroko, Mhawech-Fauceglia, Paulette, Ueda, Yutaka, Yoshino, Kiyoshi, Kajiwara, Hiroshi, Hasegawa, Kosei, Yasuda, Masanori, Miyake, Takahito M., Moriya, Takuya, Yuba, Yoshiaki, Morgan, Terry, Fukagawa, Tomoyuki, Pejovic, Tanja, Nagano, Tadayoshi, Sasaki, Takeshi, Richmond, Abby M., Post, Miriam D., Shahzad, Mian M. K., Im, Dwight D., Yoshida, Hiroshi, Enomoto, Takayuki, Omatsu, Kohei, Ueland, Frederick R., Kelley, Joseph L., Karabakhtsian, Rouzan G., and Roman, Lynda D.

Published
2018
Full Text
View/download PDF

33. Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer

Author

Kucera, Calen W., primary, Tian, Chunqiao, additional, Tarney, Christopher M., additional, Presti, Cassandra, additional, Jokajtys, Suzanne, additional, Winkler, Stuart S., additional, Casablanca, Yovanni, additional, Bateman, Nicholas W., additional, Mhawech-Fauceglia, Paulette, additional, Wenzel, Lari, additional, Hamilton, Chad A., additional, Chan, John K., additional, Jones, Nathaniel L., additional, Rocconi, Rodney P., additional, O’Connor, Timothy D., additional, Farley, John H., additional, Shriver, Craig D., additional, Conrads, Thomas P., additional, Phippen, Neil T., additional, Maxwell, G. Larry, additional, and Darcy, Kathleen M., additional

Published
2023
Full Text
View/download PDF

34. Data from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

Author

Odunsi, Kunle, primary, Matsuzaki, Junko, primary, James, Smitha R., primary, Mhawech-Fauceglia, Paulette, primary, Tsuji, Takemasa, primary, Miller, Austin, primary, Zhang, Wa, primary, Akers, Stacey N., primary, Griffiths, Elizabeth A., primary, Miliotto, Anthony, primary, Beck, Amy, primary, Batt, Carl A., primary, Ritter, Gerd, primary, Lele, Shashikant, primary, Gnjatic, Sacha, primary, and Karpf, Adam R., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table 2 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

Author

Odunsi, Kunle, primary, Matsuzaki, Junko, primary, James, Smitha R., primary, Mhawech-Fauceglia, Paulette, primary, Tsuji, Takemasa, primary, Miller, Austin, primary, Zhang, Wa, primary, Akers, Stacey N., primary, Griffiths, Elizabeth A., primary, Miliotto, Anthony, primary, Beck, Amy, primary, Batt, Carl A., primary, Ritter, Gerd, primary, Lele, Shashikant, primary, Gnjatic, Sacha, primary, and Karpf, Adam R., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure Legends from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

Author

Odunsi, Kunle, primary, Matsuzaki, Junko, primary, James, Smitha R., primary, Mhawech-Fauceglia, Paulette, primary, Tsuji, Takemasa, primary, Miller, Austin, primary, Zhang, Wa, primary, Akers, Stacey N., primary, Griffiths, Elizabeth A., primary, Miliotto, Anthony, primary, Beck, Amy, primary, Batt, Carl A., primary, Ritter, Gerd, primary, Lele, Shashikant, primary, Gnjatic, Sacha, primary, and Karpf, Adam R., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 2 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

Author

Odunsi, Kunle, primary, Matsuzaki, Junko, primary, James, Smitha R., primary, Mhawech-Fauceglia, Paulette, primary, Tsuji, Takemasa, primary, Miller, Austin, primary, Zhang, Wa, primary, Akers, Stacey N., primary, Griffiths, Elizabeth A., primary, Miliotto, Anthony, primary, Beck, Amy, primary, Batt, Carl A., primary, Ritter, Gerd, primary, Lele, Shashikant, primary, Gnjatic, Sacha, primary, and Karpf, Adam R., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

Author

Odunsi, Kunle, primary, Matsuzaki, Junko, primary, James, Smitha R., primary, Mhawech-Fauceglia, Paulette, primary, Tsuji, Takemasa, primary, Miller, Austin, primary, Zhang, Wa, primary, Akers, Stacey N., primary, Griffiths, Elizabeth A., primary, Miliotto, Anthony, primary, Beck, Amy, primary, Batt, Carl A., primary, Ritter, Gerd, primary, Lele, Shashikant, primary, Gnjatic, Sacha, primary, and Karpf, Adam R., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Table 1 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

Author

Odunsi, Kunle, primary, Matsuzaki, Junko, primary, James, Smitha R., primary, Mhawech-Fauceglia, Paulette, primary, Tsuji, Takemasa, primary, Miller, Austin, primary, Zhang, Wa, primary, Akers, Stacey N., primary, Griffiths, Elizabeth A., primary, Miliotto, Anthony, primary, Beck, Amy, primary, Batt, Carl A., primary, Ritter, Gerd, primary, Lele, Shashikant, primary, Gnjatic, Sacha, primary, and Karpf, Adam R., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Data from Coordinated Cancer Germline Antigen Promoter and Global DNA Hypomethylation in Ovarian Cancer: Association with the BORIS/CTCF Expression Ratio and Advanced Stage

Author

Woloszynska-Read, Anna, primary, Zhang, Wa, primary, Yu, Jihnhee, primary, Link, Petra A., primary, Mhawech-Fauceglia, Paulette, primary, Collamat, Golda, primary, Akers, Stacey N., primary, Ostler, Kelly R., primary, Godley, Lucy A., primary, Odunsi, Kunle, primary, and Karpf, Adam R., primary

Published
2023
Full Text
View/download PDF

43. Data from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

Author

Qian, Feng, primary, Villella, Jeannine, primary, Wallace, Paul K., primary, Mhawech-Fauceglia, Paulette, primary, Tario, Joseph D., primary, Andrews, Christopher, primary, Matsuzaki, Junko, primary, Valmori, Danila, primary, Ayyoub, Maha, primary, Frederick, Peter J., primary, Beck, Amy, primary, Liao, Jianqun, primary, Cheney, Richard, primary, Moysich, Kirsten, primary, Lele, Shashikant, primary, Shrikant, Protul, primary, Old, Lloyd J., primary, and Odunsi, Kunle, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 5 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

Author

Qian, Feng, primary, Villella, Jeannine, primary, Wallace, Paul K., primary, Mhawech-Fauceglia, Paulette, primary, Tario, Joseph D., primary, Andrews, Christopher, primary, Matsuzaki, Junko, primary, Valmori, Danila, primary, Ayyoub, Maha, primary, Frederick, Peter J., primary, Beck, Amy, primary, Liao, Jianqun, primary, Cheney, Richard, primary, Moysich, Kirsten, primary, Lele, Shashikant, primary, Shrikant, Protul, primary, Old, Lloyd J., primary, and Odunsi, Kunle, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 1 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

Author

Qian, Feng, primary, Villella, Jeannine, primary, Wallace, Paul K., primary, Mhawech-Fauceglia, Paulette, primary, Tario, Joseph D., primary, Andrews, Christopher, primary, Matsuzaki, Junko, primary, Valmori, Danila, primary, Ayyoub, Maha, primary, Frederick, Peter J., primary, Beck, Amy, primary, Liao, Jianqun, primary, Cheney, Richard, primary, Moysich, Kirsten, primary, Lele, Shashikant, primary, Shrikant, Protul, primary, Old, Lloyd J., primary, and Odunsi, Kunle, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 1 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

Author

Qian, Feng, primary, Villella, Jeannine, primary, Wallace, Paul K., primary, Mhawech-Fauceglia, Paulette, primary, Tario, Joseph D., primary, Andrews, Christopher, primary, Matsuzaki, Junko, primary, Valmori, Danila, primary, Ayyoub, Maha, primary, Frederick, Peter J., primary, Beck, Amy, primary, Liao, Jianqun, primary, Cheney, Richard, primary, Moysich, Kirsten, primary, Lele, Shashikant, primary, Shrikant, Protul, primary, Old, Lloyd J., primary, and Odunsi, Kunle, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 4 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

Author

Qian, Feng, primary, Villella, Jeannine, primary, Wallace, Paul K., primary, Mhawech-Fauceglia, Paulette, primary, Tario, Joseph D., primary, Andrews, Christopher, primary, Matsuzaki, Junko, primary, Valmori, Danila, primary, Ayyoub, Maha, primary, Frederick, Peter J., primary, Beck, Amy, primary, Liao, Jianqun, primary, Cheney, Richard, primary, Moysich, Kirsten, primary, Lele, Shashikant, primary, Shrikant, Protul, primary, Old, Lloyd J., primary, and Odunsi, Kunle, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 2 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

Author

Qian, Feng, primary, Villella, Jeannine, primary, Wallace, Paul K., primary, Mhawech-Fauceglia, Paulette, primary, Tario, Joseph D., primary, Andrews, Christopher, primary, Matsuzaki, Junko, primary, Valmori, Danila, primary, Ayyoub, Maha, primary, Frederick, Peter J., primary, Beck, Amy, primary, Liao, Jianqun, primary, Cheney, Richard, primary, Moysich, Kirsten, primary, Lele, Shashikant, primary, Shrikant, Protul, primary, Old, Lloyd J., primary, and Odunsi, Kunle, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 3 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

Author

Qian, Feng, primary, Villella, Jeannine, primary, Wallace, Paul K., primary, Mhawech-Fauceglia, Paulette, primary, Tario, Joseph D., primary, Andrews, Christopher, primary, Matsuzaki, Junko, primary, Valmori, Danila, primary, Ayyoub, Maha, primary, Frederick, Peter J., primary, Beck, Amy, primary, Liao, Jianqun, primary, Cheney, Richard, primary, Moysich, Kirsten, primary, Lele, Shashikant, primary, Shrikant, Protul, primary, Old, Lloyd J., primary, and Odunsi, Kunle, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Materials, Legends for Figures 1-5 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

Author

Qian, Feng, primary, Villella, Jeannine, primary, Wallace, Paul K., primary, Mhawech-Fauceglia, Paulette, primary, Tario, Joseph D., primary, Andrews, Christopher, primary, Matsuzaki, Junko, primary, Valmori, Danila, primary, Ayyoub, Maha, primary, Frederick, Peter J., primary, Beck, Amy, primary, Liao, Jianqun, primary, Cheney, Richard, primary, Moysich, Kirsten, primary, Lele, Shashikant, primary, Shrikant, Protul, primary, Old, Lloyd J., primary, and Odunsi, Kunle, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results